West Pharmaceutical Services (WST) Projected to Post Earnings on Thursday

Key Points

• Q1 2026 earnings are due before the market opens on April 23, with analysts modeling $1.68 EPS and $779.675M revenue and the company guiding FY2026 EPS to a 7.85–8.20 range.
• West announced a $1.0 billion share buyback authorizing repurchases of up to 5.6% of shares and declared a quarterly dividend of $0.22 per share (ex-dividend Apr 29, payable May 6; annualized $0.88, ~0.3% yield).
• The company recently beat estimates with $2.04 EPS and $805M revenue last quarter, and analysts maintain a consensus Buy rating with a $315.67 price target.

West Pharmaceutical Services (NYSE:WST - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect West Pharmaceutical Services to post earnings of $1.68 per share and revenue of $779.6750 million for the quarter. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 23, 2026 at 8:00 AM ET.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm had revenue of $805.00 million for the quarter, compared to the consensus estimate of $795.70 million. During the same quarter in the previous year, the company earned $1.82 earnings per share. The business's revenue was up 7.5% compared to the same quarter last year. On average, analysts expect West Pharmaceutical Services to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

West Pharmaceutical Services Stock Down 0.6%

WST opened at $266.45 on Thursday. West Pharmaceutical Services has a fifty-two week low of $193.05 and a fifty-two week high of $322.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34. The firm's fifty day moving average price is $247.67 and its two-hundred day moving average price is $261.55. The company has a market capitalization of $19.21 billion, a P/E ratio of 39.24, a P/E/G ratio of 2.85 and a beta of 1.15.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 12.96%.

West Pharmaceutical Services declared that its Board of Directors has initiated a share buyback plan on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.

Analysts Set New Price Targets

WST has been the subject of a number of analyst reports. Zacks Research raised West Pharmaceutical Services from a "hold" rating to a "strong-buy" rating in a report on Wednesday, January 21st. Wall Street Zen raised West Pharmaceutical Services from a "hold" rating to a "buy" rating in a report on Saturday, December 20th. UBS Group reissued a "buy" rating and set a $340.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. Evercore cut their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an "outperform" rating for the company in a report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $315.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Zions Bancorporation National Association UT increased its position in West Pharmaceutical Services by 25.3% in the fourth quarter. Zions Bancorporation National Association UT now owns 312 shares of the medical instruments supplier's stock worth $86,000 after purchasing an additional 63 shares during the period. Erste Asset Management GmbH acquired a new stake in West Pharmaceutical Services in the fourth quarter worth about $207,000. Knollwood Investment Advisory LLC acquired a new stake in West Pharmaceutical Services in the third quarter worth about $220,000. Ausdal Financial Partners Inc. acquired a new stake in West Pharmaceutical Services in the third quarter worth about $220,000. Finally, Brooklyn Investment Group grew its position in shares of West Pharmaceutical Services by 81.3% during the 3rd quarter. Brooklyn Investment Group now owns 816 shares of the medical instruments supplier's stock worth $214,000 after buying an additional 366 shares during the period. 93.90% of the stock is owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.